XLON0RC6
Market cap1.45bUSD
Jun 07, Last price
33.42EUR
Name
Pharma Mar SA
Chart & Performance
Profile
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 158,153 -19.45% | 196,343 -14.57% | 229,831 -14.87% | |||||||
Cost of revenue | 150,720 | 140,329 | 128,346 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 7,433 | 56,014 | 101,485 | |||||||
NOPBT Margin | 4.70% | 28.53% | 44.16% | |||||||
Operating Taxes | (4,760) | (5,566) | 2,270 | |||||||
Tax Rate | 2.24% | |||||||||
NOPAT | 12,193 | 61,580 | 99,215 | |||||||
Net income | 1,137 -97.70% | 49,356 -46.85% | 92,859 -32.35% | |||||||
Dividends | (11,689) | (11,761) | (10,872) | |||||||
Dividend yield | 1.59% | 1.01% | 1.05% | |||||||
Proceeds from repurchase of equity | (19,295) | 7,049 | (7,105) | |||||||
BB yield | 2.62% | -0.61% | 0.69% | |||||||
Debt | ||||||||||
Debt current | 14,805 | 14,733 | 14,031 | |||||||
Long-term debt | 32,672 | 31,519 | 39,037 | |||||||
Deferred revenue | 22,137 | 44,899 | 68,634 | |||||||
Other long-term liabilities | 896 | (284) | (293) | |||||||
Net debt | (121,147) | (152,959) | (71,002) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (13,446) | 38,321 | 25,677 | |||||||
CAPEX | (15,956) | (8,852) | (7,803) | |||||||
Cash from investing activities | (43,048) | 10,878 | 18,472 | |||||||
Cash from financing activities | (32,137) | (13,370) | (27,415) | |||||||
FCF | 520 | 68,330 | 73,073 | |||||||
Balance | ||||||||||
Cash | 162,562 | 182,420 | 201,880 | |||||||
Long term investments | 6,062 | 16,791 | (77,810) | |||||||
Excess cash | 160,716 | 189,394 | 112,578 | |||||||
Stockholders' equity | 153,251 | 167,544 | 132,338 | |||||||
Invested Capital | 105,483 | 142,658 | 183,014 | |||||||
ROIC | 9.83% | 37.82% | 51.91% | |||||||
ROCE | 2.87% | 18.03% | 34.28% | |||||||
EV | ||||||||||
Common stock shares outstanding | 17,916 | 18,063 | 18,085 | |||||||
Price | 41.08 -36.11% | 64.30 12.77% | 57.02 -19.69% | |||||||
Market cap | 735,989 -36.63% | 1,161,451 12.63% | 1,031,207 -20.74% | |||||||
EV | 614,842 | 1,008,492 | 960,205 | |||||||
EBITDA | 13,189 | 61,914 | 107,068 | |||||||
EV/EBITDA | 46.62 | 16.29 | 8.97 | |||||||
Interest | 2,416 | 2,376 | 3,373 | |||||||
Interest/NOPBT | 32.50% | 4.24% | 3.32% |